Cantor Fitzgerald Forecasts ADMA Biologics FY2026 Earnings

ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of ADMA Biologics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the biotechnology company will post earnings per share of $1.02 for the year. Cantor Fitzgerald has a "Overweight" rating and a $25.00 price objective on the stock. The consensus estimate for ADMA Biologics' current full-year earnings is $0.51 per share.

ADMA has been the topic of several other research reports. Raymond James raised their target price on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research report on Thursday, May 8th. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $24.25.

ADMA Biologics Stock Down 0.0%

NASDAQ ADMA traded down $0.01 during trading on Tuesday, reaching $20.86. 2,495,987 shares of the company's stock were exchanged, compared to its average volume of 3,659,398. The company has a 50 day moving average price of $20.71 and a two-hundred day moving average price of $18.84. The stock has a market cap of $4.98 billion, a P/E ratio of 74.50 and a beta of 0.47. ADMA Biologics has a 1 year low of $10.08 and a 1 year high of $25.67. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. During the same period last year, the business earned $0.08 EPS. The firm's revenue was up 40.2% compared to the same quarter last year.

Institutional Investors Weigh In On ADMA Biologics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mark Sheptoff Financial Planning LLC purchased a new position in shares of ADMA Biologics during the fourth quarter worth approximately $35,000. Skandinaviska Enskilda Banken AB publ purchased a new position in ADMA Biologics during the 1st quarter worth $35,000. SVB Wealth LLC acquired a new position in ADMA Biologics in the first quarter valued at $35,000. Smartleaf Asset Management LLC raised its holdings in shares of ADMA Biologics by 161.4% in the first quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock valued at $49,000 after buying an additional 1,493 shares during the last quarter. Finally, Vision Financial Markets LLC purchased a new stake in shares of ADMA Biologics in the fourth quarter valued at about $51,000. Hedge funds and other institutional investors own 75.68% of the company's stock.

Insider Transactions at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 7,779 shares of the company's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $20.32, for a total value of $158,069.28. Following the completion of the sale, the director now directly owns 114,830 shares of the company's stock, valued at $2,333,345.60. This represents a 6.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 3.50% of the company's stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.